Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,835 | $12,766 | $15,569 | $17,712 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | $7,616 | $3,102 | $926 | $933 |
| Gross Profit | $21,219 | $9,664 | $14,643 | $16,779 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | $11,816 | $10,075 | $7,454 | $5,931 |
| G&A Expenses | $16,015 | $9,965 | $4,377 | $3,940 |
| SG&A Expenses | $16,015 | $9,965 | $4,377 | $3,940 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,189 | -$850 | -$624 | $3,133 |
| Operating Expenses | $26,642 | $19,190 | $11,207 | $13,004 |
| Operating Income | -$5,423 | -$9,526 | $3,436 | $3,775 |
| % Margin | -18.8% | -74.6% | 22.1% | 21.3% |
| Other Income/Exp. Net | $761 | -$1,154 | -$2,358 | -$3,342 |
| Pre-Tax Income | -$4,662 | -$10,680 | $1,078 | $433 |
| Tax Expense | $176 | -$3,487 | $696 | -$584 |
| Net Income | -$4,838 | -$7,193 | $382 | $1,017 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.95 | -87.18 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.8% | -62.7% | – |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 90 | 83 | 82 | 81 |
| Weighted Avg Shares Out Dil | 90 | 83 | 83 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,544 | $1,341 | $663 | $199 |
| Interest Expense | $783 | $2,495 | $756 | $3,797 |
| Depreciation & Amortization | $3,984 | $2,478 | $1,345 | $1,278 |
| EBITDA | $105 | -$5,707 | $3,179 | $8,188 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |